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ABSTRACT
Introduction Cardiopulmonary exercise testing (CPET) 
provides a series of biomarkers, such as peak oxygen 
uptake, which could assess the development of disease 
status in interstitial lung disease (ILD). However, despite 
use in research and clinical settings, the feasibility of CPET 
in this patient group has yet to be established.
Methods Twenty- six patients with ILD (19 male) 
were recruited to this study. Following screening for 
contraindications to maximal exercise, participants 
underwent an incremental CPET to volitional exhaustion. 
Feasibility of CPET was assessed by the implementation, 
practicality, acceptability and demand, thus providing 
clinical- driven and patient- driven information on this 
testing procedure.
Results Of the 26 recruited participants, 24 successfully 
completed at least one CPET, with 67/78 prospective tests 
being completed. Contraindications included hypertension, 
low resting oxygen saturation and recent pulmonary 
embolism. Of the CPETs undertaken, 63% successfully 
reached volitional exhaustion, with 31% being terminated 
early by clinicians due to excessive desaturation. 
Quantitative and qualitative feedback from participants 
revealed a positive experience of CPET and desire for it to 
be included as a future monitoring tool.
Conclusion CPET is feasible in patients with ILD. 
Identification of common clinical contraindications, and 
understanding of patient perspectives will allow for 
effective design of future studies utilising CPET as a 
monitoring procedure.
INTRODUCTION
Interstitial lung disease (ILD) is the collec-
tive term for a series of pulmonary disorders 
characterised by inflammation, interstitial 
and alveolar damage, and often irreversible 
declines in lung function, with idiopathic 
pulmonary fibrosis (IPF) being the most 
common subtype of ILD, affecting ~32 500 
people and accounting for 1% of all deaths 
in the UK.1
Traditionally, measures of pulmonary 
function, including forced vital capacity 
(FVC) and the diffusing capacity for carbon 
monoxide (DLCO), have been used to monitor 
disease progression and evaluate the efficacy 
of treatments. Both variables are predictive 
of mortality2 and provide greater predictive 
power for survival over 6 months than histo-
pathological factors alone.3 However, peak 
oxygen uptake (VO2peak), the primary outcome 
from cardiopulmonary exercise testing 
(CPET), is also associated with mortality4 and 
is therefore an important variable to consider 
alongside traditional resting spirometry.
For CPET to be integrated into clinical 
practice, it must be shown to be a feasible 
procedure and well tolerated by patients 
undergoing the test—an important consider-
ation given its exhaustive nature. Therefore, 
this study (Exploring the potential of Cardio 
Pulmonary Exercise Testing as a biomarker 
in patients diagnosed with Fibrosing Lung 
Disease) sought to assess the feasibility of 
CPET, notably the implementation, practi-
cality, acceptability and demand, in a cohort 
of patients with ILD.
METHODS
Design and population
This feasibility study examined practicali-
ties and safety associated with performing 
CPET in individuals with ILD. The study was 
designed to have participants perform three 
Key messages
 ► Is cardiopulmonary exercise testing safe, practi-
cal and acceptable to patients with interstitial lung 
disease?
 ► This modality of exercise testing provides novel 
physiological data in addition to traditional spirom-
etry and should be considered as a future biomarker 
for use in this clinical population.
 ► This study provides important clinical data on safety, 
and the valuable patient perspective on the accept-
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CPETs in a 6- month period, with 3 months separating 
each test.
The inclusion criteria for this study were as follows: 
(1) clinical diagnosis of fibrotic lung disease as deter-
mined by the Royal Devon and Exeter ILD Team; (2) 
40–85 years. of age; (3) FVC >40%; (4) DLCO >25%; (5) 
willing and able to provide informed consent. Exclu-
sion criteria included: (1) unable/unwilling to provide 
informed consent; (2) left or right ventricular ejection 
fraction <50%; more than mild valvular heart disease; 
lack of available chest CT images; (3) significant repolar-
isation abnormalities or arrhythmias identified by resting 
12- lead ECG or untoward ECG changes and/or symptoms 
of ischemia during previous baseline testing of CPET; 
(4) significant neurological impairment (anything that 
prevents patients from cycling); (5) poorly controlled 
(symptomatic) asthma, or recent exacerbation of asthma 
(requiring hospitalisation or medical therapy) within 
the preceding 4 weeks; (6) severe cardiovascular comor-
bidity or other medical conditions that could contribute 
to dyspnoea, (7) forced expiratory volume in 1 s/FVC 
(FEV1/FVC) ratio <65%; (8) daytime oxygen therapy; (9) 
contraindications to exercise testing.
Consequently, 26 patients with ILD (19 male) were 
recruited. Of these 26, n=13 were currently taking antifi-
brotic medication (nintedanib, n=10; pirfenidone, n=3). 
Further patient characteristics and diagnoses are listed 
in table 1.
All participants provided written and informed consent 
on recruitment to the study.
Physiological measures
Stature and body mass were assessed using standard 
methods, with body mass index (BMI) subsequently 
calculated. Body fat percentage was assessed using air 
displacement plethysmography (BodPod; COSMED, 
Rome, Italy), with subsequent values for fat mass and fat- 
free mass (FFM) calculated.
Measures of FEV1, FVC and DLCO were retrospectively 
extracted from pulmonary function test (PFT) data from 
each participant’s medical records at the date closest to 
their CPET. Data are presented as absolute values and as 
a per cent of a predicted value for age, sex, and stature. 
In addition, composite ‘Gender- Age- Physiology’ scores,5 
were also calculated for each participant.
Cardiopulmonary exercise testing
Participants performed a CPET on an electroni-
cally braked cycle ergometer (Lode Excalibur; Lode, 
Groningen, the Netherlands), undertaking an incre-
mental protocol as per existing international guidelines.6 
Participants performed 3 min unloaded cycling (0 W) as 
a warm- up, before an incremental ramp phase whereby 
resistance increased by 10 W/min. Participants main-
tained a cadence between 60 and 80 revolutions per 
minute (rpm) until volitional exhaustion, defined as a 
decrease in cadence >10 rpm for five consecutive seconds 
despite verbal encouragement from research staff. On 
exhaustion, participants returned to unloaded cycling at 
0 W for a further 3 min to cool down. On cessation of 
unloaded cycling, participants recovered in a seated posi-
tion off of the cycle ergometer for approximately 10 min. 
Once recovered, and with permission from the attending 
doctor, participants were free to leave.
Throughout CPET, pulmonary gas exchange was 
recorded using a metabolic cart (Medgraphics Ultima; 
Medical Graphics UK Ltd., Gloucester, UK). Data were 
measured breath- by- breath and analysed in 10 s averages. 
Normative values7 were utilised to present VO2peak and 
peak work rate (WRpeak) as a percentage of predicted.
Participant safety
Prior to CPET, all participants were clinically screened 
for contraindications to maximal exercise (eg, hyperten-
sion). Furthermore, all participants wore a 12- lead ECG 
(Welch Allyn CardioPerfect; Hillrom, Chicago, USA) and 
pulse oximeter (Choice MMed MD300C2; ChoiceMMed, 
Dusseldorf, Germany), to monitor cardiac changes and 
peripheral capillary oxygen saturation (SpO2), respec-
tively. All CPETs were supervised by an exercise phys-
iologist and medical doctor, and the CPET was termi-
nated if either ECG (eg, arrhythmia) or SpO2 responses 
warranted early cessation for patient safety. In the first 
round of CPETs, the SpO2 limit was conservatively set at 
<88%, and extended to <80% in the second and third 
CPETs. This latter cut- off aligns with international guide-
lines,6 as hypoxaemia was also shown to be well tolerated 
in the first CPET; any adverse symptoms (should they 
have occurred) also provided clinicians with reasons for 
CPET termination in addition to desaturation.
Feasibility
Feasibility was assessed using existing guidelines,8 
predominantly by focusing on ‘implementation’ (degree, 
and success/failure, of execution of CPET), ‘practicality’ 
(ability of participants to perform CPET, with focus 
on safety), ‘acceptability’ (perceived appropriateness 
of CPET), and ‘demand’ (expressed interest in use of 
CPET).
Each of these components were measures in differing 
ways:
1. Implementation of CPET was assessed by (A) identify-
ing reasons, and their number, as to why participants 
did not undertake CPET, and (B) identifying reasons, 
and their number, for clinician- led termination of 
CPET.
2. Practicality was assessed by characterising the number 
of excessive ECG and SpO2 changes during CPET.
3. Acceptability and demand were established by iden-
tifying participant opinions on satisfaction with, and 
suitability of, CPET for future use. This was under-
taken as part of an evaluation of the wider study (full 
questionnaire provided in online supplemental file 1 
and was completed using two processes.
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19 2 3 1 1
13 2 2 1 1
6 0 1 0 0
12 0 0 1 0
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a. First, support for three brief statements, were eval-
uated on a 7- point Likert scale with a balanced 
number of positive and negative response options, 
whereby 1=‘strongly disagree’ and 7=‘strongly 
agree’. These included: (1) ‘The exercise test was 
too physically challenging for someone with my 
lung condition’, (2) ‘Based on my experience in 
this trial, I think CPET is feasible for lung disease 
patients’ and (3) ‘The idea of using exercise testing 
to develop individualised exercise programmes for 
patients does not appeal to me’. Participants were 
encouraged to provide additional reflections on 
these questions.
b. Second, qualitative responses from a semi- structured 
interview were examined, with particular focus on 
the question ‘How did you find the exercise test, 
and if you have done other exercise tests (like the 
shuttle walk test), which do you prefer and why?’
Statistical analyses
Baseline anthropometric, pulmonary and clinical data 
were compared between (1) males and females, and 
(2) participants on antifibrotic medication and those 
that were not. This was undertaken using independent 
samples t- tests to infer any homogeneity (or heteroge-
neity) in the sample. Effect sizes, using existing thresh-
olds9 were also utilised to infer trivial (<0.2), small 
(0.2<0.5), medium (0.5<0.8) and large (≥0.8) differences 
between groups. Paired samples t- tests identified changes 
in SpO2 in each CPET.
Pearson’s correlations were utilised to establish rela-
tionships between parameters of fitness, and nadir and 
change in SpO2; as well as between SpO2 values at the 
start and end of CPETs. Magnitudes of coefficients were 
described as small (0.1<0.3), medium (0.3<0.5) and large 
(≥0.5).9 All analyses were undertaken using SPSS V.26 
(IBM), and a p<0.05 was considered significant.
Patient and public involvement
There is no patient or public involvement (PPI) to 
report in the design of this feasibility project, however, 
a questionnaire (online supplemental file 1) was used 
to assess experiences of participation within the trial, as 
previously mentioned in the ‘Feasibility’ section above.
RESULTS
Participants
Participant characteristics are listed in table 1. Significant 
differences were observed between males and females 
for stature, absolute FEV1 and FVC, body fat percentage 
and FFM. Based on use of antifibrotic medication, signif-
icant differences were found for participants on antifi-
brotic medication who had both a lower body mass and 
BMI. However, there were no differences to be observed 
between groups for pulmonary function when normal-
ised to percent predicted (table 1).
At baseline, mean (±SD) parameters of fitness for 
the n=24 to successfully complete one CPET were as 
follows for VO2peak; 1.32±0.40 L/min; 16.6±5.1 mL/kg/
min; 26.4±6.8 mL/kgFFM/min; 76.6%±22.5%Predicted. 
For WRpeak, mean values were as follows: 92±37 W; 
1.16±0.50 W/kg; 65.6%±23.8%Predicted.
The mean time difference between CPET and PFTs 
across the course of the study was 33±95 days (0.09±0.26 
years), indicating that, on average, PFTs and CPET were 
separated by 1 month.
Feasibility: implementation
Two participants were excluded from performing CPET 
at their baseline visit by the attending clinician (hyper-
tension, n=1; resting SpO2 <90%, n=1), resulting in n=24 
undertaking at least one CPET. At the second visit, two 
further CPETs were not undertaken due to voluntary 
withdrawal of a participant (citing a lack of energy; n=1) 
and a participant experiencing a pulmonary embolism 
within the 4 weeks prior to study visit (n=1). At the 
third visit, three CPETs were not undertaken due to the 
aforementioned participant withdrawal (n=1), signifi-
cant participant exertional desaturation (SpO2 <80%) 
on exertion (n=1), and one participant passed away in 
between study visits (n=1). Exclusions resulted in 67/78 of 
possible CPETs from the recruited n=26 being completed 
(figure 1) – an 86% completion rate.
For n=21 participants who undertook all three CPETs, 
the mean duration between visits 1 and 2 was 26±12 weeks 
(range=12–49 weeks). Between visits 2 and 3, this mean 
duration was 15±5 weeks (10–28 weeks). Finally, mean 
duration between the first and last CPET was 41±14 weeks 
(23–65 weeks).
The majority of CPETs undertaken were satisfactorily 
completed, as patients successfully reached volitional 
exhaustion (n=42, 63%), compared with a number of 
participants who failed to reach exhaustion and tests were 
terminated by clinical staff. These reasons for clinical 
cessation included excessive desaturation (n=21, 31%), 
right bundle branch block (n=1, 1%) and a poor ECG 
trace, leading to a precautionary termination (n=1, 1%). 
Figure 1 Flow chart detailing inclusion, exclusion and 
withdrawal of participants during study period. CPET, 
cardiopulmonary exercise testing; SpO2, oxygen saturation.
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One patient experienced excessive musculoskeletal pain 
(n=1, 1%) and one reason was not recorded (n=1, 1%).
Feasibility: practicality
Desaturation during exercise occurred in 63/67 CPETs, 
with n=3 CPETs experiencing no desaturation, and n=1 
increasing SpO2 during the CPET (from 90% to 91%) as 
shown in figure 2. No relationship was evident between 
SpO2 at rest, and nadir SpO2 at termination of the CPET 
(figure 2). Nadir SpO2 and changes (Δ) in SpO2 held 
small to medium correlations with markers of fitness, as 
shown by relationships with WRpeak and VO2peak (table 2) 
Figure 2 Left: changes in peripheral capillary oxygen saturation (SpO2) from rest (pre) to end of test (post) for each CPET. 
Horizontal line at 80% indicates termination threshold for CPET as per American Thoracic Society (ATS)/American College of 
Chest Physicians (ACCP) recommendations. P value derived from repeated measures t- test. right: correlation between values 
of SPO2 at rest (pre) and end of CPET (post). All correlations presented as Pearson’s coefficient (r) and associated p value. 
PET, cardiopulmonary exercise testing.
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when all n=67 CPETs were pooled for analysis. No signif-
icant correlations were reported when separated out by 
individual CPET.
In addition to the aforementioned right bundle branch 
block leading to CPET termination, ECG readings during 
the course of CPETs also revealed atrial fibrillation (n=1); 
possible atrial fibrillation (n=1); poor R- wave progression 
(n=1); T- wave inversion (n=1); asymptomatic widening 
of the QRS complex accompanied by T- wave inversion 
(n=1); and asymptomatic ventricular bigeminy (n=2), 
although these were not a cause for immediate CPET 
cessation. Referrals for 24- hour ECG monitoring were 
subsequently made by the attending clinical staff.
During exercise, all participants were able to main-
tain the pedalling rate as instructed, and the majority of 
individuals self- selected a cadence of 60–70 rpm, while 
two participants selected a cadence >70 rpm. Postexer-
cise, one participant reported dizziness, although this 
ceased after a 5 min period and did not re- occur in subse-
quent CPETs. No other postexercise complications were 
reported.
Feasibility: acceptability and demand
A total of n=19 participants completed the post- trial 
evaluation. Of those to respond, participants rated their 
involvement in the study highly, and responded positively 
to the questions aimed at evaluating CPET. Responses 
for each question (mean±SD, range) were as follows: 
Q1 (1.5±0.6, 1–3), Q2 (6.7±0.5, 6–7), Q3 (1.7±1.3, 1–6). 
Qualitative reflections to the three questions are provided 
in table 3.
Furthermore, in response to the semi- structured inter-
view, participants reflected on their perspectives on the 
CPET, and in relation to other testing modalities. Broadly, 
CPET was viewed on positively:
I felt quite able and capable of doing it – the results 
will show but I was able to exert as much as I could and 
Table 2 Correlations between desaturation and 
parameters of fitness during cardiopulmonary exercise 
testing in patients with interstitial lung disease
Nadir SpO2 ΔSpO2




























Values presented are Pearson’s correlation coefficients for n = 67 
successfully completed CPETs.
FFM, fat free mass; SpO2, peripheral capillary oxygen saturation; 
VO2peak, peak oxygen uptake; WRpeak, peak work rate.
Table 3 Selected qualitative responses to questions pertaining to exercise testing within the trial evaluation
Question Direct participant quotes
‘The exercise test was too 
physically challenging for 
someone with my lung 
condition’
 ► “I was fine – it depends what level you’re at”
 ► “I think I could do more than I did from the lung point of view – my legs gave out first”
 ► “It helps me to know how I feel”
 ► “The whole purpose of this exercise is for people who have a weakness in their body 
system”
‘Based on my experience in this 
trial, I think cardiopulmonary 
exercise testing is feasible for 
lung disease patients’
 ► “I think there are certain people who wouldn’t be able to manage it, although carers can 
hold patients back with their views about what the patient can do”
 ► “Oh yeah, and I think it’s an interesting thing to watch - to know what’s happening to your 
heart. Sometimes I’ve been thinking is it my heart or is it my lungs when I’ve been feeling 
really poorly”
 ► “I think it is essential and it should become compulsory”
‘The idea of using exercise 
testing to develop individualised 
exercise programmes for 
patients does not appeal to me’
 ► “I may not want to adhere to an exercise programme”
 ► “It gives me confidence. I’ve leapt at the chance to do the pulmonary rehab here! (The 
physical therapist) here described it and it sounded exactly what I need to get my 
confidence back to do stuff - they said it’s OK to get out of breath, whereas you think you 
can’t because it’s the PF (pulmonary fibrosis). How you exercise safely is a paradox for 
me. It’s feeling that you’re not allowed to with PF”
 ► “Apart from playing bowls and gardening; I’m not likely to start playing football again!”
 ► “I know it’s good for you, but you have to motivate yourself to do it”















es: first published as 10.1136/bm





Tomlinson O, et al. BMJ Open Resp Res 2021;8:e000793. doi:10.1136/bmjresp-2020-000793 7
Open access
as long as I could – there must’ve been a parameter 
in which I was performing fairly well or they wouldn’t 
have allowed me to go on so long
I think the bike test is really good because it gives you 
so much information
For the most part, enjoyable! It obviously gets harder, 
but you’re allowed to stop so that’s alright
There were also some negative comments related to 
the testing procedures:
The bike test was OK – I was a little bit disappointed 
that they had to stop it [because of a right bundle 
block]
[the CPET] Very good – except the seat – that bicycle 
seat is most uncomfortable
Compared with other testing modalities, CPET was 
preferred to shuttle walks:
I prefer this definitely – it’s a tougher examination of 
your ability to move yourself and breathe. It’s a more 
accurate examination of your ability, more detailed. 
The shuttle walk test didn’t push me
I prefer the exercise bike test – the level of monitoring 
is much more detailed than a six min walk test
I don’t think they compare really because the shuttle 
walk test was very easy – it didn’t feel like a test really
The walk test is a nonsense – the bicycle test you are 
measuring everything, stamina, heart rate, the whole 
response, oxygen test, you’re doing everything. The 
walk test – you can choose how fast you walk – I could 
have gone on walking for a long time and it was up to 
me to choose the pace
I did the six minute walk test a lot in the trials – that 
always went OK. I loved doing the bike!
CPET was also preferred to spirometry:
Compared with spirometry, it’s easier – in [another 
hospital] I did two sorts – the one where you breathe 
in the mixture of gases and breathe out, one where 
you hold your breath out very quickly – but I thought 
the bike was better than that
Finally, spirometry was viewed on negatively by some:
[the spirometry] depends on who you’ve got taking 
it and you know what’s going to happen and it’s 
very hard to hold your breath when you‘ve got stuff 
blowing down the back of your throat; I don’t think 
it’s a very good indication of your health. I don’t like 
it at all.
The static lung function tests are very daunting and 
unpleasant to undergo
Patient and public involvement
While there was no PPI in the initial design of this study, 
general feedback from involvement in the trial revealed 
a desire from patients to be involved in future research 
and therefore a new patient- driven, research steering 
group was established (Exeter Patients in Collaboration 
for Pulmonary Fibrosis Research) in conjunction with 
the Royal Devon and Exeter National Health Service 
Foundation Trust and the College of Medicine & Health, 
University of Exeter. This group will be utilised to code-
sign trials following the outcome of this feasibility study.
DISCUSSION
This study aimed to assess the feasibility, namely the 
implementation, practicality, acceptability and demand, 
of CPET in patients with ILD. The results have shown 
CPET can be feasibly undertaken in individuals with ILD, 
and is widely accepted by patients, therefore highlighting 
its prospective use as an alternative biomarker in this 
condition.
The feasibility of CPET was assessed with regards to 
clinically- driven, as well as patient- reported outcomes. 
First, evaluation of the implementation and practicality 
provides an objective assessment of whether this test 
could be used in a routine clinical setting, rather than a 
research- only environment. A successful 86% completion 
rate was achieved, and of the 11 tests not undertaken, 
six were due to immediate exclusion of participants at 
baseline due to contraindications, with a further two 
CPETs fitting this category from subsequent visits. The 
remaining three were accounted for by patient death and 
withdrawal from the study itself. These exclusions align 
with established absolute and relative contraindications 
to maximal exercise,6 although the authors are not aware 
of any previous studies to characterise the contraindica-
tions to exercise in ILD. Co- morbidities, including atrial 
fibrillation (which was also identified in our present 
cohort) have been reported in a previous study to use 
CPET, although this appears to be from a descriptive, 
rather than exclusionary perspective.10 This study also 
stated, unlike further CPET- based studies,4 11 12 that exer-
cise was stopped by a clinician if necessary, although there 
is no further elaboration on any reasons if this occurred. 
Therefore, the present study is unique and advances our 
understanding in characterising clinical factors respon-
sible for exclusion from, or cessation of, CPET in patients 
with ILD.
Within the current CPETs, the majority of partici-
pants desaturated, although only 31% to such an exces-
sive extent that exercise had to be terminated, with the 
magnitude of desaturation in line with previous studies 
(eg, 87.7%±5.7%11; 90%±6%.13 Given that international 
recommendations propose exercise is terminated if SpO2 
<80%,6 it is reassuring that our present results conform 
with previous studies and international guidelines, and 
that our patient group appears to be exercising safely 
within accepted norms, only prematurely stopping CPET 
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in one- third of cases. In our sample, we noted two partic-
ipants that presented with a normal pattern of desatu-
ration, prior to a rapid drop in SpO2. For these two 
participants, CPET was terminated when SpO2 reached 
80%, although this value continued to drop for ~5 s, 
resulting in two abnormally low nadir SpO2 values as seen 
in figure 2. This unexpected drop in SpO2 values was rare 
(ie, 2/67 CPETs), but it is important for clinicians to be 
aware of this potential risk. Future trials could consider 
the use of supplemental oxygen during CPET to offset 
this risk of desaturation (provided any equipment is tech-
nically compatible); although such hyperoxic conditions 
may affect the implementations of tests, and interpreta-
tion of results.14
Previous research has also suggested the degree to 
which patients desaturate during exercise testing is 
associated with baseline SpO2,
15 although this does not 
appear to be supported in the present study as baseline 
and end- exercise SpO2 were not significantly correlated, 
even at the final CPET (figure 2), when disease severity 
may have progressed over the intervening period of time 
(up to 65 weeks for some participants). Moreover, desat-
uration and markers of fitness (VO2peak, WRpeak) held 
only small to medium correlations (table 2) – even when 
pooling all CPETs for increased power –indicating a level 
of homogeneity in the desaturation response to exer-
cise in ILD. Thus, it is possible that disease presentation 
and severity has little effect on the risk of desaturation 
during exercise, and that alternative, non- disease related, 
mechanisms may be responsible and worthy of further 
investigation.
The prognostic value of CPET has been established 
previously, with VO2peak
4 11 and VE/VCO2
12 being predic-
tive of mortality in patients with IPF; and CPET is reported 
to be reproducible in restrictive lung disease.16 There-
fore, this highlights the need to consider physiological 
measures, and not solely rely on radiological outcomes 
when monitoring fibrotic interstitial diseases and their 
subsequent change over time.3 17 Furthermore, as exer-
cise intolerance in ILD is multifactorial,18 use of CPET 
can be utilised to ascertain causes of intolerance, as well 
as informing personalised approaches towards pulmo-
nary rehabilitation and exercise regimens in patients.19
A personalised approach to exercise training was 
received with a mixed response in our cohort, with the 
mean score suggesting participants agreed with the prin-
ciple of personalised regimens, although the qualitative 
responses provided contrasting views. Previous inter-
views of individuals with IPF show that patients feel exer-
cise could benefit them physically and mentally, while 
proposing a preference for group- exercise,20 aligning 
with some of the perspectives put forward in the present 
study. Furthermore, current pulmonary rehabilitation 
guidelines state that personalisation is warranted to 
optimise such programmes.21 Therefore, CPET can be 
utilised to inform these processes, as the testing process 
itself has also been shown to be widely accepted in the 
present study.
Furthermore, a common theme that emerged was in 
relation to preference of CPET over alternative exercise 
tests, as well as spirometry, for which there appeared to 
be a dislike among this cohort of participants. While PFT 
are well established processes for detecting and char-
acterising changes in disease status,22 and remain the 
gold- standard outcome measure in respiratory medicine, 
previous research reported that patients present with 
anxiety in relation to such tests,23 and find it difficult to 
translate such test results in relation to future exercise 
and activity ability.24 While the authors do not advocate 
for the removal, nor replacement of spirometry from 
clinical practice, a case can certainly be made for CPET 
to exist as an adjunct clinical measure alongside tradi-
tional PFT, for the benefit of clinicians and patients alike.
There are both strengths and limitations to be discussed 
with this study. Our study provides real- life data on how 
CPET is tolerated in this patient group, and thus provides 
clinicians with valuable insight into how to ingrain this 
modality of testing into services, and what contraindica-
tions and responses to anticipate. Moreover, the combina-
tion of quantitative and qualitative assessments not only 
empower the patient population and their voice within 
research and routine clinical assessment; but the descrip-
tion of physiological changes and logistical challenges 
associated with CPET, will prove exceptionally useful to 
the wider ILD community.
In contrast, we acknowledge that a sample size of 26 
individuals can be interpreted as a limitation. This group 
is relatively homogeneous with regards to pulmonary 
function (as shown by lack of differences between sexes 
and antifibrotic usage in table 1) and can be considered 
mild in nature, with a sample that is composed predomi-
nantly of males with IPF. Therefore, there is a possibility 
this sample may not truly reflect wider patients responses 
to, and acceptability towards, CPET. However, previous 
exercise- based feasibility studies in ILD have recruited 
similar (or fewer) patient numbers,25 26 and thus our study 
is in line with such similarly designed studies. Moreover, 
given that IPF is the most common progressive ILD, and 
is more common in males,27 28 we conclude our sample is 
broadly reflective of the wider ILD population.
CONCLUSION
In conclusion, this study has shown CPET to be feasible 
within a clinical setting in terms of implementation and 
practicality, identifying reasons (and their number) for 
excluding patients from CPET, or stopping an exercise 
bout prematurely. Furthermore, CPET is acceptable by 
the intended user group (those with ILD). Therefore, 
this testing procedure should be considered for future 
use as an additional biomarker to evaluate prognosis and 
response to treatments in this patient population.
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PETFIB Patient View Questionnaire 
 
‘PETFIB’ is a trial to explore the potential of Cardio Pulmonary Exercise Testing as a biomarker 
in patients with a clinical diagnosis of FIBrosing lung disease. During the trial, we monitored 
how your lungs worked during a test on a stationary bike, and your health in general (weight, 
and blood tests) over several months   
 
We are asking you these questions so we can understand your experience of participation in 
the PETFIB trial and to hear your views on the use of exercise testing to help with monitoring 
of patients with lung disease. Your answers will help us design future trials and inform how we 
assess the health of patients routinely. 
 
The questionnaire is divided into two sections, one involving numerical scoring (some 









Please indicate how you 













 1 2 3 4 5 6 7 
When I first heard about 
this trial I was keen to be 
involved 
       
My early understanding of 
what the trial would 
involve turned out to be 
unrealistic. 
       
The exercise test was too 
physically challenging for 
someone with my lung 
condition 
       
I was keen to complete the 
full trial despite medical 
and other challenges 
       
I have felt unsupported by 
the research team during 
my participation. 
       
Once I had given consent 
to be involved in the trial, I 
felt I could withdraw at any 
time 
       
Overall, involvement in the 
trial was a positive 
experience for me. 
       
Based on this experience, 
it is unlikely that I shall 
volunteer for future trials. 
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Please indicate how you 













 1 2 3 4 5 6 7 
I would advise other 
patients with similar 
conditions not to get 
involved in clinical trials 
like this. 
       
Based on my experience 
in this trial, I think 
cardiopulmonary exercise 
testing is feasible for lung 
disease patients. 
       
The idea of using exercise 
testing to develop 
individualised exercise 
programmes for patients 
does not appeal to me 
       
 
Section 2 
Please reflect on the trial and answer the questions below.  
 








3. How did you find the bike exercise tests and if you’ve done other exercise tests (like the 
















7. What else would you like to say or think is important? 
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